Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report

Li,Gui-dong; Ogose,Akira; Hotta,Tetsuo; Kawashima,Hiroyuki; Ariizumi,Takashi; Xu,Yongjun; Endo,Naoto

doi:10.3892/ol.2011.369

Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report

Authors:
- Gui-dong Li
- Akira Ogose
- Tetsuo Hotta
- Hiroyuki Kawashima
- Takashi Ariizumi
- Yongjun Xu
- Naoto Endo
View Affiliations

Affiliations: Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata 951-8510, Japan
Published online on: August 2, 2011 https://doi.org/10.3892/ol.2011.369
Pages: 1239-1242

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polyostotic fibrous dysplasia (PFD) is a high-turnover bone disease that frequently entails chronic bone pain, pathological fractures and severe deformities. Recently, bisphosphonates have shown effective antiresorptive properties in the treatment of children or adults with PFD. We report on a 79-year‑old female with PFD, who had severe lower limb deformity and chronic bone pain in multiple sites of her extremities for more than 55 years. The patient experienced significant decrease in bone pain and bone turnover markers following long‑term (8.5 years) treatment with a low-dose oral alendronate treatment (5 mg/day). To the best of our knowledge, this is the first report of a long-term follow-up of a postmenopausal elderly patient with long-standing symptomatic PFD following continuous low-dose oral alendronate therapy. This case report indicates that long-term daily administration of low-dose alendronate alone is a potential treatment option for elderly patients with PFD, particularly those with long‑standing bone pain.

View Figures

View References

1	Marie PJ, de Pollak C, Chanson P and Lomri A: Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol. 150:1059–1069. 1997.
2	Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P and Gehron Robey P: Osteoclastogenesis in fibrous dysplasia of bone: In situ and in vitro analysis of IL-6 expression. Bone. 33:434–442. 2003. View Article : Google Scholar : PubMed/NCBI
3	Lane JM, Khan SN, O'Connor WJ, et al: Bisphosphonate therapy in fibrous dysplasia. Clin Orthop. 382:6–12. 2001. View Article : Google Scholar : PubMed/NCBI
4	Isaia GC, Lala R, Defilippi C, et al: Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int. 71:121–128. 2002. View Article : Google Scholar : PubMed/NCBI
5	Chapurlat RD, Hugueny P, Delmas PD and Meunier PJ: Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone. 35:235–242. 2004. View Article : Google Scholar : PubMed/NCBI
6	Chapurlat RD: Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 21(Suppl 2): 114–119. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yamomoto T, Ozono K, Shima M, Yoshikawa H and Okada S: Alendronate and pharmacological doses of 1 alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia. J Bone Miner Metab. 20:170–173. 2002. View Article : Google Scholar : PubMed/NCBI
8	Khadilkar VV, Khadilkar AV and Maskati GB: Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr. 40:894–896. 2003.PubMed/NCBI
9	Kitagawa Y, Tamai K and Ito H: Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci. 9:521–525. 2004. View Article : Google Scholar : PubMed/NCBI
10	Aragão AL and Silva IN: Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report. Int J Pediatr Endocrinol. Oct 4–2010.(E-pub ahead of print).
11	Harris WH, Dudley HR Jr and Barry RJ: The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study. J Bone Joint Surg Am. 44:A207–A233. 1962.PubMed/NCBI
12	Sissons HA and Malcolm AJ: Fibrous dysplasia of bone: case report with autopsy study 80 years after the original clinical recognition of the bone lesions. Skeletal Radiol. 26:177–183. 1997.PubMed/NCBI
13	Szendrói M, Rahóty P, Antal I and Kiss J: Fibrous dysplasia associated with intramuscular myxoma (Mazabraud's syndrome): a long-term follow-up of three cases. J Cancer Res Clin Oncol. 124:401–406. 1998.
14	Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R and Glorieux FH: Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 88:4569–4575. 2003. View Article : Google Scholar : PubMed/NCBI
15	Collins MT, Kushner H, Reynolds JC, et al: An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res. 20:219–226. 2005. View Article : Google Scholar : PubMed/NCBI